Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03518554 · ClinicalTrials.gov registry record · Phase 1
A First in Human, Dose Escalation Study of JAB-3068 （SHP2 Inhibitor） in Adult Patients With Advanced Solid Tumors
A Phase 1 study of Non-Small Cell Lung Cancer and Head and Neck Cancer, sponsored by Jacobio Pharmaceuticals Co..
- Completed
- Registry status
- Phase 1
- Development phase
- 38
- Enrollment target
- 4
- Study locations
NCT03518554 is a Phase 1 study of Non-Small Cell Lung Cancer and Head and Neck Cancer that has completed, run by Jacobio Pharmaceuticals Co.. The registered enrollment target is 38 participants, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (94% lower). The trial reports 4 study locations across 4 states.
The verdict
NCT03518554, a Phase 1 study of Non-Small Cell Lung Cancer and Head and Neck Cancer, has completed, sponsored by Jacobio Pharmaceuticals Co..
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 38 participants
- Enrollment target
- 4
- Study locations
Study Summary
This is a phase 1, multi-center, dose escalation, open-label study to evaluate the safety, tolerability, pharmacokinetics, and preliminary evidence of antitumor activity of JAB-3068 in adult patients with advanced solid.
Conditions Studied
Interventions
- DRUG JAB-3068
Study Locations (4)
Colorado
- HealthONE Clinic Services Oncology-Hematology - Denver
Florida
- Florida Cancer Specialists - Sarasota
Tennessee
- Sarah Cannon Research Institute - Nashville
Texas
- The University of Texas M. D. Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2018-04-23 |
| Est. Completion | 2022-02-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03518554
The ClinicalTrials.gov registry entry for NCT03518554 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (94% lower). The listed sponsor is Jacobio Pharmaceuticals Co., which has 7 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which JAB-3068 is the first listed.
NCT03518554 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Colorado, Florida, Tennessee.
Frequently Asked Questions
What is clinical trial NCT03518554 about?
NCT03518554 is a clinical study titled "A First in Human, Dose Escalation Study of JAB-3068 （SHP2 Inhibitor） in Adult Patients With Advanced Solid Tumors". This is a phase 1, multi-center, dose escalation, open-label study to evaluate the safety, tolerability, pharmacokinetics, and preliminary evidence of antitumor activity of JAB-3068 in adult patients with advanced solid.
What is the current status of trial NCT03518554?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 38 participants. The study started on 2018-04-23. Estimated completion is 2022-02-03.
What conditions does trial NCT03518554 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, Head and Neck Cancer, Esophageal Cancer, Other Metastatic Solid Tumors.
What interventions are being tested in trial NCT03518554?
The interventions under investigation include: JAB-3068 (DRUG).
Who is sponsoring clinical trial NCT03518554?
This trial is sponsored by Jacobio Pharmaceuticals Co., which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03518554 being conducted?
This trial has 4 study locations across Colorado, Florida, Tennessee, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
RECRUITING · Phase 1
-
Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC
RECRUITING · Phase 1
-
A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
RECRUITING · Phase 1
-
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
RECRUITING · Phase 1
-
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.